Q-omics provides the consensus-scored DCXR-DT profile across patient tissues and cancer cell-line models. DCXR-DT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, DCXR-DT is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DCXR-DT RNA expression shows 13,917 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, KIRC, and ACC as cancer lineages where DCXR-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCXR-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCXR-DT survival associations across molecular data types. DCXR-DT RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCXR-DT RNA expression–survival associations across cancer types. High DCXR-DT expression shows unfavorable associations in ACC, KIRC, ESCA and UCS, but favorable associations in BRCA and KIRP. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for DCXR-DT RNA expression.
This table summarizes DCXR-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DCXR-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCXR-DT shows lower tumor expression in KIRC, KIRP, THCA, KICH and CHOL and higher tumor expression in COAD. The KIRC box plot shows higher DCXR-DT RNA expression in normal versus tumor tissue (log2 FC = −1.305, t-test p < 0.001).
This table shows molecular features associated with DCXR-DT in patient tissues and cancer cell lines. In patient samples, DCXR-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
